Denali Therapeutics
-
FDA presses pause on test of Alzheimer’s drug from Denali before study even starts
The FDA placed a clinical hold on Denali Therapeutics’ application to begin Phase 1 testing of an antibody drug for Alzheimer’s disease. The Denali drug uses the biotech’s proprietary technology to deliver therapeutic cargo across the protective blood-brain barrier.
-
Flagship Pioneering forges ahead with $618M capital raise
The capital raise is the culmination of a year that was punctuated with two of its portfolio companies filing initial public offerings and the hire of J.P. Morgan veteran Stephen Berenson.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Startups, BioPharma, Policy, Payers
New standards for genetic testing, get your fill of the Denali dream team (Morning Read)
Get the latest: FDA outlines genetic testing standards, everyone writes about Denali and California moves on a batter vaccination bill.